Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* 20 to 45 years old~* Body Mass Index of 18.5 kg/m2 and less than or equal to 29.9 kg/m2~* Others~Exclusion Criteria:~* Known history of hypersensitivity to human growth hormone (hGH)~* Known history of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, immunological, hepatic or renal disease, or malignancies~* Others

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ACP-001, dose-level 1 (Type: EXPERIMENTAL): None
- ACP-001, dose-level 2 (Type: EXPERIMENTAL): None
- ACP-001, dose-level 3 (Type: EXPERIMENTAL): None
- ACP-001, dose-level 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).